ALK and ARS Pharmaceuticals sign a deal giving ALK global rights to Neffy nasal spray outside key regions, targeting peak sales of around $400 million in anaphylaxis treatment.

In June, the FDA expanded the approval of GSK's RSV vaccine (Arexvy) to include adults ages 50-59 at increased risk of lower ...

The US Food and Drug Administration announced a proposal to remove oral phenylephrine – a common ingredient in many popular ...

The FDA is warning that patients taking GLP-1s may be at a higher risk of inhaling fluid into their lungs while under ...

The U.S. Food and Drug Administration has proposed to remove oral phenylephrine, widely used in cold and cough syrups, as an ...

Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...

This update in the health sector highlights major developments including DiaSorin's significant profit growth, GSK's RSV ...

Moderna MRNA is set to report third-quarter 2024 earnings on Nov. 7, before the opening bell. The Zacks Consensus Estimate ...

RSV season is upon us, which means thousands of children under five years of age and hundreds of thousands of adults will be ...

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...

GSK has lowered its vaccine sales forecast for the year because of weak demand for its new respiratory syncytial virus jab Arexvy, sending the pharmaceutical group’s shares down more than 3 per cent ...

GSK reported a mixed third-quarter performance on Wednesday, with a notable boost from specialty medicines helping to offset ...